Wnt/?-Catenin signaling as a driver of hepatocellular carcinoma progression: an emphasis on molecular pathways

Basit Öğe Kaydı
dc.authoridAli Zarrabi / 0000-0003-0391-1769en_US
dc.authorscopusidAli Zarrabi / 23483174100
dc.authorwosidAli Zarrabi / U-2602-2019
dc.contributor.authorDeldar Abad Paskeh, Mahshid
dc.contributor.authorMirzaei, Sepideh
dc.contributor.authorAshrafizadeh, Milad
dc.contributor.authorZarrabi, Ali
dc.contributor.authorSethi, Gautam
dc.date.accessioned2021-12-06T08:01:22Z
dc.date.available2021-12-06T08:01:22Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Mühendislik ve Doğa Bilimleri Fakültesi, Biyomedikal Mühendisliği Bölümüen_US
dc.description.abstractLiver cancers cause a high rate of death worldwide and hepatocellular carcinoma (HCC) is considered as the most common primary liver cancer. HCC remains a challenging disease to treat. Wnt/?-catenin signaling pathway is considered a tumor-promoting factor in various cancers; hence, the present review focused on the role of Wnt signaling in HCC, and its association with progression and therapy response based on pre-clinical and clinical evidence. The nuclear translocation of ?-catenin enhances expression level of genes such as c-Myc and MMPs in increasing cancer progression. The mutation of CTNNB1 gene encoding ?-catenin and its overexpression can lead to HCC progression. ?-catenin signaling enhances cancer stem cell features of HCC and promotes their growth rate. Furthermore, ?-catenin prevents apoptosis in HCC cells and increases their migration via triggering EMT and upregulating MMP levels. It is suggested that ?-catenin signaling participates in mediating drug resistance and immuno-resistance in HCC. Upstream mediators including ncRNAs can regulate ?-catenin signaling in HCC. Anti-cancer agents inhibit ?-catenin signaling and mediate its proteasomal degradation in HCC therapy. Furthermore, clinical studies have revealed the role of ?-catenin and its gene mutation (CTNBB1) in HCC progression. Based on these subjects, future experiments can focus on developing novel therapeutics targeting Wnt/?-catenin signaling in HCC therapy.en_US
dc.identifier.citationDeldar Abad Paskeh, M., Mirzaei, S., Ashrafizadeh, M., Zarrabi, A., & Sethi, G. (2021). Wnt/β-Catenin Signaling as a Driver of Hepatocellular Carcinoma Progression: An Emphasis on Molecular Pathways. Journal of hepatocellular carcinoma, 8, 1415–1444.en_US
dc.identifier.doi10.2147/JHC.S336858en_US
dc.identifier.endpage1444en_US
dc.identifier.pmid34858888en_US
dc.identifier.startpage1415en_US
dc.identifier.urihttps://doi.org/10.2147/JHC.S336858
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2303
dc.identifier.volume8en_US
dc.identifier.wosWOS:000723700600001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorZarrabi, Ali
dc.language.isoenen_US
dc.publisherDove Medical Pressen_US
dc.relation.ispartofJournal of Hepatocellular Carcinomaen_US
dc.relation.publicationcategoryDiÄŸeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectWnt Signalingen_US
dc.subjectDrug Resistanceen_US
dc.subjectImmunotherapyen_US
dc.subjectLiver Canceren_US
dc.subjectNon-coding RNAsen_US
dc.titleWnt/?-Catenin signaling as a driver of hepatocellular carcinoma progression: an emphasis on molecular pathwaysen_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
Ä°sim:
35.pdf
Boyut:
8.04 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
Ä°ndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
Ä°sim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
Ä°ndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Biyomedikal Mühendisliği Bölümü Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu